Scope
The final ASH guideline addresses newly diagnosed acute myeloid leukaemia in older adults, from treatment selection through remission, transplantation and transfusion support. Decisions depend on fitness for conventional induction, molecular findings, prognosis and patient goals. Strong recommendations and conditional suggestions are distinguished below. The final published article identifies this as the 2026 guideline, superseding the earlier 2025 label on prepublication materials.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Define the population and treatment goals
- The evidence population is newly diagnosed de novo, treatment-related or secondary AML in adults aged ≥55 years. Relapsed or refractory AML, acute promyelocytic leukaemia and Down-syndrome-associated myeloid neoplasms are outside this evidence population. [1]
- For an older adult with newly diagnosed AML who is a candidate for antileukaemic treatment, offer treatment over best supportive care alone: a strong recommendation with moderate-certainty evidence, retained from the earlier guideline without a new evidence review. [1]
- Discuss treatment in relation to the patient’s values and priorities, including survival and disease control, toxicity, hospital stays and quality of life. The panel stresses shared decision-making because patients weigh these outcomes differently. [1]
Choose an induction and postremission approach
- For patients eligible for conventional intensive treatment, ASH conditionally favours conventional induction and postremission therapy over HMA or low-dose cytarabine monotherapy. When the alternative includes venetoclax, either conventional therapy or an HMA/low-dose cytarabine–venetoclax combination is suggested. [1]
- Favourable-risk cytogenetic or molecular disease, tolerance of a long hospital stay and younger age within the older population may favour conventional treatment. Older age, certain poor-risk abnormalities or a preference to avoid admission may favour a venetoclax combination; these are considerations rather than rigid eligibility rules. [1]
- After remission following at least one cycle of conventional induction, give postremission therapy rather than no further treatment if the patient is not a candidate for allogeneic transplantation. This recommendation is strong, with low-certainty evidence. [1]
Options when conventional treatment is unsuitable
- When antileukaemic treatment is appropriate but conventional induction/postremission therapy and HMA-based combination therapy are unsuitable, ASH conditionally favours azacitidine monotherapy over low-dose cytarabine monotherapy, and 5-day over 10-day decitabine monotherapy. [1]
- When antileukaemic treatment is appropriate but conventional induction/postremission therapy is unsuitable, ASH conditionally favours an HMA with venetoclax over HMA alone. [1]
- When conventional treatment and HMA-based combinations are unsuitable, ASH conditionally favours low-dose cytarabine with venetoclax over low-dose cytarabine alone. [1]
Match treatment comparisons to the mutation
- For newly diagnosed IDH1-mutated AML when antileukaemic treatment is appropriate but conventional induction/postremission treatment is unsuitable, ASH conditionally favours azacitidine plus ivosidenib over azacitidine alone. It suggests either an HMA–ivosidenib or an HMA–venetoclax combination; it does not prefer one of those combinations. [1]
- For newly diagnosed IDH2-mutated AML when antileukaemic treatment is appropriate but conventional induction/postremission treatment is unsuitable, ASH conditionally favours azacitidine alone over azacitidine–enasidenib, and HMA–venetoclax over HMA–enasidenib. [1]
- For FLT3-mutated disease, ASH conditionally favours adding an FLT3 inhibitor to antileukaemic therapy. This primarily concerns conventional induction and postremission treatment; net benefit is less certain with HMA or low-dose cytarabine regimens, including venetoclax combinations. [1]
Continue treatment, consider transplant and support goals of care
- After a response to HMA- or low-dose cytarabine–based induction and postremission therapy, ASH conditionally suggests continuing until progression or unacceptable toxicity, rather than stopping after a fixed number of cycles. [1]
- ASH conditionally suggests allogeneic transplantation when the patient has responded to initial treatment, is a transplant candidate in first remission, and has a nonfavourable karyotypic and molecular prognosis. All these conditions belong to the recommendation. [1]
- Make red-cell transfusions available to older adults no longer receiving antileukaemic treatment, including hospice or end-of-life care: a conditional recommendation retained without a new evidence review. Platelet transfusions may rarely help with bleeding, but supporting data are even more limited and their expected end-of-life role is small. [1]
Limitations and use
- This is a treatment-selection summary of the final published recommendation text and remarks. It does not specify complete chemotherapy doses, drug-interaction management, monitoring schedules or supportive-care protocols.
- The comparison groups and candidacy conditions must be preserved. A suggestion favouring one regimen over a named comparator is not a recommendation for every patient with AML. Most conditional recommendations have low or very-low certainty.
- The final publication is labelled 2026. Earlier pocket materials labelled 2025 and marked Not For Distribution were excluded as the clinical basis.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute myeloid leukaemia in older adults
Guideline recommendation text consulted
Publication details
- Issuing organisation
- ASH
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.